The 34 most recent market catalysts affecting $DHR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 55
Tiger Global Management Increases Stake in Danaher Corporation
Tiger Global Management, a well-known investment firm, has increased its holdings in Danaher Corporation to 1.3 million shares. This move is significant as it reflects a vote of co…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 55
Danaher Companies IDT and Aldevron Launch New mRNA Solutions for Gene Editing
Danaher's subsidiaries, IDT and Aldevron, have introduced new mRNA solutions for base and prime editing, leveraging their combined strengths in CRISPR engineering and mRNA manufact…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 55
Cepheid Receives FDA Clearance for Xpert Hemorrhagic Fever Panel
Cepheid, a subsidiary of Danaher, has received FDA clearance for its Xpert Hemorrhagic Fever Panel. This is a positive development as it expands Cepheid's diagnostic product offeri…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 55
Beckman Coulter Diagnostics Receives FDA Clearance for Access MeMed BV® Assay
Beckman Coulter Diagnostics, a subsidiary of Danaher Corporation, announced FDA clearance for its Access MeMed BV® assay. This new diagnostic tool helps clinicians distinguish betw…
Oct 28, 2026
Corporate Catalyst
Bearish
Impact 55
Evercore ISI Adjusts Price Target on Danaher to $205 From $242
Evercore ISI has reduced its price target for Danaher (DHR) from $242 to $205. This action reflects a revised valuation assessment by the analyst firm, suggesting a potentially les…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 55
HSBC Adjusts Price Target on Danaher to $260 From $250
HSBC adjusted its price target for Danaher Corporation (DHR) upwards from $250 to $260. This action reflects an updated valuation outlook by the analyst firm, suggesting a slightly…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
JPMorgan Adjusts Danaher Price Target to $270
JPMorgan, a prominent financial institution, has raised its price target for Danaher Corporation (DHR) from $250 to $270. This adjustment is a direct result of the firm's updated v…
Oct 22, 2026
Corporate Catalyst
Neutral
Impact 55
Genedata Integrates RFD4-Proteina Binder Design Model into AI Discovery Workflows
Genedata, a subsidiary of Danaher, has integrated the RFD4-Proteina binder design model into its AI discovery workflows. This is significant as it positions Genedata as an early ad…
Oct 22, 2026
Corporate Catalyst
Neutral
Impact 65
Multiple Financial Institutions Adjust Price Targets for Danaher Corporation
On October 22, 2026, several prominent financial firms, including Goldman Sachs, TD Cowen, Stifel, Citigroup, Leerink Partners, and Barclays, all raised their price targets for Dan…
Oct 21, 2026
Corporate Catalyst
Bearish
Impact 75
Danaher shares are trading lower after the company reported mixed Q3 financial results.
Danaher's mixed Q3 results are a significant corporate catalyst, directly impacting its stock price negatively. The 'mixed' nature implies some segments performed well while others…
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 75
Danaher Sees Q4 2026 Non-GAAP Core Revenue Excluding Respiratory Revenue Up 4%-5% YoY
Danaher (DHR) has disclosed its expectation for Q4 2026 non-GAAP core revenue, excluding respiratory revenue, to grow by 4-5% year-over-year. This is a significant forward-looking …
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 75
Danaher Raises FY2026 Adj EPS Guidance from $8.45-$8.60 to $8.57-$8.62 vs $8.51 Est
Danaher announced an upward revision to its adjusted EPS guidance for fiscal year 2026, moving the range from $8.45-$8.60 to $8.57-$8.62. This new guidance also surpasses the curre…
Oct 19, 2026
Corporate Catalyst
Bearish
Impact 65
Danaher Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
This filing is an earnings preview for Danaher (DHR) ahead of its Q3 report on October 21st. Analysts are projecting a modest increase in EPS and a more significant jump in revenue…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 65
Danaher Brings NVIDIA AI Into Scientific Instruments in Push for Faster Discoveries
Danaher Corporation announced a strategic collaboration with NVIDIA to integrate NVIDIA's AI capabilities into Danaher's scientific instruments and laboratory software. This initia…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Danaher, Raises Price Target to $240
Morgan Stanley's analyst Kallum Titchmarsh maintained an 'Overweight' rating on Danaher (DHR) and raised the price target from $220 to $240. This action signals continued confidenc…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Danaher, Raises Price Target to $255
TD Cowen analyst Dan Brennan maintained a 'Buy' rating on Danaher (DHR) and raised the price target from $236 to $255. This action signals continued confidence in Danaher's perform…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Danaher, Raises Price Target to $255
Barclays analyst Luke Sergott has maintained an 'Overweight' rating on Danaher (DHR) and raised the price target from $230 to $255. This action signals continued confidence from a …
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 75
Danaher shares are trading higher after RBC Capital raised its price target on the stock from $215 to $250.
This headline indicates a significant positive corporate catalyst for Danaher. An analyst upgrade from a reputable firm like RBC Capital, especially with a substantial increase in …
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Danaher, Raises Price Target to $250
RBC Capital's analyst maintaining an 'Outperform' rating and raising the price target for Danaher (DHR) indicates a strong belief in the company's fundamentals and future growth pr…
Oct 1, 2026
Market Technicals
Bullish
Impact 55
Guggenheim Maintains Buy on Danaher, Raises Price Target to $250
Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Danaher (DHR) and raised the price target from $200 to $250. This action signals increased confidence from a promine…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 65
Tiger Global Management Takes New Stake In Danaher Corp With 456,000 Shares.
This headline indicates a significant institutional investor, Tiger Global Management, has initiated a new position in Danaher Corp. This can be seen as a positive signal for Danah…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Danaher shares are trading higher after the company announced it appointed Julie Sawyer Montgomery as President and CEO.
The appointment of a new President and CEO for a company of Danaher's size and market capitalization is a significant corporate catalyst. Investors often react positively to new le…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 75
Danaher Appoints Julie Sawyer Montgomery As President, CEO, Effective Oct. 1, Succeeding Rainer Blair
Danaher Corporation has announced a planned CEO transition, with Julie Sawyer Montgomery taking over from Rainer Blair on October 1, 2026. This is a significant leadership change f…
Jul 24, 2026
Corporate Catalyst
Bearish
Impact 75
Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
Billionaire investor Daniel Loeb's decision to significantly cut his stake in Danaher and fully exit Thermo Fisher Scientific in Q1 2026 indicates a bearish outlook on the Life Sci…
Jul 22, 2026
Market Technicals
Bearish
Impact 65
Stock Of The Day: Is The Danaher Selloff Over?
Danaher (DHR) experienced a significant stock price drop of over 10% yesterday due to a weak earnings report, accompanied by unusually high trading volume. This filing interprets t…
Jul 22, 2026
Market Technicals
Bearish
Impact 55
TD Cowen Maintains Buy on Danaher, Lowers Price Target to $236
This filing indicates that TD Cowen's analyst Dan Brennan has maintained a 'Buy' rating on Danaher (DHR), signaling continued confidence in the company's long-term prospects. Howev…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Danaher, Raises Price Target to $215
RBC Capital analyst Dan Leonard maintained an 'Outperform' rating on Danaher (DHR) and raised the price target from $200 to $215. This action signals a continued bullish sentiment …
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 85
Transcript: Danaher Q2 2026 Earnings Conference Call
Danaher's Q2 2026 earnings call transcript reveals a robust performance, exceeding expectations in revenue, earnings, and cash flow. The company's decision to raise its full-year a…
Jul 21, 2026
Corporate Catalyst
Bearish
Impact 92
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Danaher (DHR) reported Q2 adjusted EPS of $1.94, beating estimates of $1.83, and sales of $6.265 billion, topping estimates of $6.102 billion. Despite these strong results, the sto…
Jul 21, 2026
Corporate Catalyst
Bearish
Impact 75
Danaher shares are trading lower. The company reported Q2 financial results.
This headline signifies a direct corporate catalyst, as Danaher's Q2 financial results are driving its stock performance. The 'trading lower' indicates that the results likely disa…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 75
Danaher Sees Q3 Non-GAAP Core Revenue To Increase In 2.0% To 3.0% Range YoY, And FY26 Non-GAAP Core Revenue To Increase In 3.0% To 4.0% Range YoY
Danaher's guidance for non-GAAP core revenue growth, particularly the multi-year FY26 outlook, provides a positive signal for the company's long-term trajectory. While the growth r…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 75
Danaher Raises FY2026 Adj EPS Guidance from $8.35-$8.55 to $8.45-$8.60 vs $8.45 Est
Danaher (DHR) has raised its adjusted EPS guidance for fiscal year 2026, indicating a more optimistic outlook for its future financial performance. This upward revision, albeit mod…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.